Immune System Diseases

The site conducts extensive research on immune system diseases, targeting conditions such as multiple sclerosis, myasthenia gravis and other autoimmune disorders. Trials aim to assess novel biologic agents, compare long‑term safety profiles and explore new mechanisms of disease modulation.

  • Evaluation of anti‑CD20 therapies including ublituximab
  • Head‑to‑head comparison of remibrutinib versus standard disease‑modifying treatments
  • Pharmacokinetic and pharmacodynamic studies of biosimilar ocrelizumab
  • Investigation of BTK inhibition with SAR442168 in progressive forms of MS

Research is carried out at Neuro‑Medic Sp. z o.o. in Katowice, Poland, with 21 active trials and a dedicated team of two investigators.

Musculoskeletal Diseases

Studies focus on musculoskeletal diseases that cause chronic pain and functional impairment, including low back pain, post‑surgical neuropathic pain and diabetic peripheral neuropathy. The primary goal is to identify effective analgesic strategies and improve quality of life for patients with refractory pain.

  • Dose‑response characterization of VER‑01 for chronic non‑specific low back pain
  • Topical capsaicin (Qutenza) versus low‑dose control for post‑surgical neuropathic pain
  • Medical cannabis aerosol containing THC for diabetic peripheral neuropathic pain
  • Single‑injection botulinum toxin (IPN10200) for upper‑limb spasticity after stroke or brain injury

The clinic’s multidisciplinary approach integrates pain specialists and rehabilitation experts to advance therapeutic options.

Nervous System Diseases

The research program addresses a broad spectrum of nervous system diseases, from neurodegenerative disorders such as Alzheimer’s disease to various forms of multiple sclerosis and post‑stroke spasticity. Trials are designed to test innovative drugs, evaluate disease‑modifying effects and reduce neurological disability.

  • Assessment of masupirdine for agitation in Alzheimer’s disease
  • Long‑term safety and efficacy of ocrelizumab in primary progressive MS
  • Effectiveness of frexalimab in relapsing‑remitting multiple sclerosis
  • Evaluation of serum neurofilament (sNfL) as a biomarker of disease activity

Ongoing investigations aim to slow progression, improve functional outcomes and provide new therapeutic avenues for patients with complex neurological conditions.

Physiological Processes

Research also explores fundamental physiological processes underlying disease activity, emphasizing biomarkers and advanced imaging techniques. The objective is to refine diagnostic tools, monitor treatment response and predict clinical trajectories.

  • Serum neurofilament light chain (sNfL) dynamics in multiple sclerosis
  • Quantitative MRI analysis of new T1 Gd‑enhancing lesions
  • Whole‑brain atrophy measurement using SIENA in progressive MS
  • Pharmacokinetic profiling of subcutaneous versus intravenous administration routes

These studies support personalized medicine by linking physiological markers with therapeutic outcomes.